These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32338779)

  • 1. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open.
    Peng C; Jiexin L; Yue W; Benhong Z
    Aliment Pharmacol Ther; 2020 May; 51(10):996-997. PubMed ID: 32338779
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
    Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
    Aliment Pharmacol Ther; 2020 May; 51(10):997-998. PubMed ID: 32338784
    [No Abstract]   [Full Text] [Related]  

  • 3. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.
    Kotze PG; Teixeira FV; Damião AOMC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1208-1209. PubMed ID: 32424919
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.
    Panaccione R; Abreu MT; Lazariciu I; Mundayat R; Lawendy N; Salese L; Woolcott JC; Sands BE; Chaparro M
    Aliment Pharmacol Ther; 2022 Jun; 55(12):1534-1544. PubMed ID: 35246988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.
    Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1209-1210. PubMed ID: 32424928
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: new insights on tofacitinib dose de-escalation.
    Amiot A
    Aliment Pharmacol Ther; 2020 Mar; 51(5):578. PubMed ID: 32048759
    [No Abstract]   [Full Text] [Related]  

  • 8. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
    Hanauer S; Panaccione R; Danese S; Cheifetz A; Reinisch W; Higgins PDR; Woodworth DA; Zhang H; Friedman GS; Lawendy N; Quirk D; Nduaka CI; Su C
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):139-147. PubMed ID: 30012431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis.
    Verstockt B; Van Hemelen M; Outtier A; Sabino J; Van Wijngaerden E; De Munter P; Ferrante M; Wilmer A; Vermeire S
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2294-2297. PubMed ID: 32918841
    [No Abstract]   [Full Text] [Related]  

  • 10. IBD: Tofacitinib effective in ulcerative colitis.
    Bradley CA
    Nat Rev Gastroenterol Hepatol; 2017 Jul; 14(7):388. PubMed ID: 28513630
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of tofacitinib treatment in ulcerative colitis.
    Panés J; Gisbert JP
    Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis.
    Griller N; Cohen L
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1213. PubMed ID: 31003697
    [No Abstract]   [Full Text] [Related]  

  • 13. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.
    Esfahani K; Hudson M; Batist G
    N Engl J Med; 2020 Jun; 382(24):2374-2375. PubMed ID: 32521140
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
    Tsai HH
    Aliment Pharmacol Ther; 2018 Feb; 47(4):539-540. PubMed ID: 29341281
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
    Le Berre C; Loeuille D; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):794-796. PubMed ID: 30114486
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):540-541. PubMed ID: 29341277
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
    Lo SW; Connell W; Kamm MA; Lust M; Wright EK
    Aliment Pharmacol Ther; 2021 Aug; 54(4):532-533. PubMed ID: 34331806
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
    Biemans VBC; Straatmijer T; Hoentjen F; Pierik MJ
    Aliment Pharmacol Ther; 2021 Aug; 54(4):534-535. PubMed ID: 34331810
    [No Abstract]   [Full Text] [Related]  

  • 19. Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
    Guillo L; Peyrin-Biroulet L; Louis E
    J Crohns Colitis; 2021 Jul; 15(7):1087-1088. PubMed ID: 33619541
    [No Abstract]   [Full Text] [Related]  

  • 20. Tofacitinib for the treatment of ulcerative colitis.
    Fernández-Clotet A; Castro-Poceiro J; Panés J
    Expert Rev Clin Immunol; 2018 Nov; 14(11):881-892. PubMed ID: 30285500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.